JNJ - Johnson & Johnson
| Previous close | 139.50 |
| Open | 138.34 |
| Bid | 138.70 x 900 |
| Ask | 139.30 x 800 |
| Day's range | 137.91 - 140.00 |
| 52-week range | 118.62 - 148.32 |
| Volume | 5,924,814 |
| Avg. volume | 6,185,213 |
| Market cap | 373.038B |
| Beta (3Y Monthly) | 0.53 |
| PE ratio (TTM) | 276.44 |
| EPS (TTM) | 0.50 |
| Earnings date | 11 Oct 2016 - 17 Oct 2016 |
| Forward dividend & yield | 3.60 (2.58%) |
| Ex-dividend date | 2018-08-27 |
| 1y target est | 145.63 |
Market Realist•yesterdayAn Overview of JNJ’s Women’s Health & Wound Care Businesses
Johnson & Johnson’s (JNJ) women’s health business generated revenue of $269.0 million in the third quarter compared to $270.0 million in the third quarter of 2017. In the US and international markets in the quarter, the business generated revenues of $3.0 million and $266.0 million, respectively.
Market Realist•yesterdayA Performance Overview of JNJ’s Beauty and OTC Businesses
Johnson & Johnson’s (JNJ) beauty business generated revenue of $1.1 billion in the third quarter compared to $1.0 billion in the third quarter of 2017, reflecting a ~4.4% YoY rise.
- Motley Fool•yesterday
What's Behind Johnson & Johnson's Q3 Earnings Success
Here's why this healthcare giant is out-performing analyst expectations.
- Market Realist•yesterday
What’s Pfizer’s Current Valuation?
In this part, we’ll compare Pfizer’s (PFE) valuation with its peers including Merck (MRK), Johnson & Johnson (JNJ), Eli Lilly (LLY), and Bristol-Myers Squibb (BMY).
- Market Realist•yesterday
Pfizer’s Dividends and Earnings Quality
In this part, we’ll discuss Pfizer’s (PFE) earnings quality and dividend performance. The above chart compares the changes in Pfizer’s Earnings Quality score since the first quarter of 2017. Pfizer has announced the following dividends during 2018.
- Market Realist•yesterday
Pfizer Reported Revenue Growth in Global Markets
Pfizer (PFE) reported revenue growth in international markets during the second quarter. Lower sales from US markets offset the growth during the quarter.
- Motley Fool•2 days ago
Can UnitedHealth Group and Johnson & Johnson Continue Their Winning Ways?
How these healthcare giants beat industry watchers' estimates last quarter and their plans for the future.
- Market Realist•2 days ago
Pfizer’s Growth Rate and Estimates
Pfizer (PFE) reported an EPS of $0.74 on revenues of ~$13.5 billion during the second quarter, which beat analysts’ estimate of ~$13.3 billion.
- Zacks•2 days ago
Johnson & Johnson, Community Healthcare Trust: Income Stocks to Watch
Ryan McQueeney puts two income stocks --- Johnson & Johnson (JNJ) and Community Healthcare Trust (CHCT)---in the spotlight this week. JNJ delivered impressive earnings a few days back, while CHCT is an interesting REIT to watch in current conditions.
- Market Realist•2 days ago
Novartis Missed Revenue Estimates in Q3 2018
Novartis (NVS) released its third-quarter earnings results on October 18. The company surpassed Wall Street analysts’ consensus estimate for EPS but missed their estimate for revenue in the quarter. Novartis reported EPS of $1.32 on revenue of ~$12.78 billion compared to analysts’ estimate of EPS of $1.31 on revenue of ~$13.02 billion.
- Market Realist•2 days ago
Pfizer’s Market Cap and Shareholding Pattern
As we discussed earlier, Pfizer’s (PFE) product portfolio is classified into two segments—the Innovative Health segment and the Essential Health segment. In this part, we’ll discuss Pfizer’s market capitalization and shareholding pattern.
- Market Realist•2 days ago
Analyzing Pfizer’s Stock Performance in October
Pfizer (PFE) is one of the leading healthcare companies. Pfizer stock increased 1.5% and closed at $44.57 on October 17—compared to the previous close.
- Motley Fool•3 days ago
2 Big Pharmas Pleased With J&J's Third-Quarter Earnings Report
Johnson & Johnson's latest earnings report suggests pricing concerns in the U.S. are overblown for pharmaceutical stocks with strong oncology exposure. Here's what you need to know.
- Zacks•3 days ago
Stock Market News For Oct 17, 2018
Wall Street rebounded on Tuesday as stocks surged across the board due to strong third-quarter 2018 earnings results and impressive economic data.
Associated Press•4 days agoAsian shares climb on strong US corporate earnings, data
SINGAPORE (AP) — Asian markets rose on Wednesday as robust U.S. corporate earnings and encouraging data assuaged worries about softening global growth.
- Motley Fool•4 days ago
3 Stocks for Warren Buffett Fans
If you want to be like Buffett, here's a healthcare stock, an auto company, and an airline for you.
- Motley Fool•4 days ago
What Happened in the Stock Market Today
Stocks bounced back, with investors encouraged by earnings reports from companies like Morgan Stanley and Johnson & Johnson.
- Associated Press•4 days ago
UnitedHealth, Johnson & Johnson and Morgan Stanley jump
Stocks that moved substantially or traded heavily on Tuesday: Johnson & Johnson, up $2.61 to $136.56 The health care products company reported higher sales of prescription drugs. Goldman Sachs Group Inc., ...
- Investor's Business Daily•4 days ago
Stocks Surge At The Bell: Adobe Leads, 4 Dow Stocks Rattle And Hum
The Nasdaq led stocks higher Tuesday as Adobe spiked and Dow stocks buzzed after Johnson & Johnson, UnitedHealth and Goldman Sachs reported.
- Investor's Business Daily•4 days ago
Stock Market Storms Higher, But Can The Rally Be Trusted?
The stock market was sharply higher late Tuesday, helped in part by strong earnings from top stocks in the Dow like UnitedHealth Group and Johnson & Johnson.
Motley Fool•4 days agoJohnson & Johnson (JNJ) Q3 2018 Earnings Conference Call Transcript
JNJ earnings call for the period ending September 30, 2018.
Market Realist•4 days agoJohnson & Johnson Reports Strong Q3 Results, Stock Rises
Johnson & Johnson Reports Strong Q3 Results, Stock RisesJohnson & Johnson’s third-quarter earnings
- Zacks•4 days ago
Will Tuesday's Earnings Reports Inspire a Stock Market Rebound?
Ryan McQueeney recaps the morning's top pre-market earnings reports from Goldman Sachs, Morgan Stanley, and Johnson & Johnson. Later, he is joined by Zacks Strategist Dave Bartosiak to discuss upcoming reports from Netflix and IBM.
- Motley Fool•4 days ago
Johnson & Johnson Looks Healthier Than Ever
Sizable sales gains came from an unexpected part of the healthcare conglomerate's business.
Associated Press•4 days agoPrescription drugs, lower taxes, power J&J 3Q beat
A jump in prescription drug sales and a sharply reduced tax bill boosted Johnson & Johnson's third-quarter sales and profit, which beat Wall Street expectations. The world's biggest maker of health care products on Tuesday also slightly raised its profit forecast for the year. The New Brunswick, N.J., maker of baby products, biotech drugs and medical devices reported net income of $3.93 billion, or $1.44 per share, up 4.5 percent from a year earlier.
